You are here: Home » Companies » News
Business Standard

USFDA completes inspection of Cadila Healthcare's Ahmedabad facility

Shares of Cadila Healthcare closed at Rs 264.05 per scrip on the BSE, up 1.46 per cent from its previous close

Press Trust of India  |  New Delhi 

Cadila Healthcare
Cadila Healthcare

Drug firm on Tuesday said the inspection of its manufacturing facility at Ahmedabad by the US health regulator was completed with no observations.

United States Food and Drug Administration (USFDA) inspected the manufacturing facility of Alidac Pharmaceuticals, the company's wholly-owned subsidiary, at SEZ, Ahmedabad from January 27 to February 4, 2020, said in a BSE filing.

"At the end of the inspection, no observation (483) is issued. The site manufactures oncology injectables for the regulated markets," it added.

Shares of closed at Rs 264.05 per scrip on the BSE, up 1.46 per cent from its previous close.

First Published: Tue, February 04 2020. 20:02 IST
RECOMMENDED FOR YOU